(HealthDay News) — For patients with heart failure with reduced ejection fraction and predominantly central sleep apnea, adaptive servo-ventilation does not improve outcome, according to a study ...
Please provide your email address to receive an email when new articles are posted on . Treatment with adaptive servo-ventilation for 12 months improved disease-specific quality of life scores. At 12 ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO, Fla. — In a substudy of CAT-HF, patients with HF, sleep-disordered breathing and an implantable cardiac ...
LONDON, UK — Researchers are urging clinicians to stop the use in clinical practice of adaptive servo ventilation (ASV) for central sleep apnea (CSA) in HF patients with reduced ejection fraction ...
On May 15, 2015, Respironics, Inc., a Philips business, provided the following response to ResMed's Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea ...
Adaptive servo-ventilation (ASV) therapy increases mortality and should not be used to treat central sleep apnea in heart failure patients with reduced ejection fraction, the SERVE-HF trial shows.
ResMed announced primary results from a multicenter, randomized controlled phase II trial known as CAT-HF presented at the European Society of Cardiology's 2016 Annual Heart Failure Congress. CAT-HF ...
The results of the first randomized, controlled trial to assess adaptive servo-ventilation (ASV) for central sleep apnoea were expected to confirm the positive findings from previous observational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results